![](https://images.squarespace-cdn.com/content/v1/54c68ac6e4b06d2e36a4b8c9/1585411667181-4DAUOCOD82BM712P2DRA/image-asset.jpeg)
LATEST NEWS IN PROSTATE CANCER
Targeted Radiation Administered by Injection
Radium-223 Dichloride, otherwise known as Xofigo, is the first alpha-emitting radiopharmaceutical used to treat prostate-cancer-related bone metastasis. The FDA approved Xofigo in May of 2013. The clinical trial that led to the FDA approval was called the ALSYMPCA trial. Eligible patients were randomized in a 2:1 fashion to either receive six monthly intravenous injections of radium-223 or best standard of care, such as antiandrogen hormonal therapy, local external beam radiation, corticosteroids, estramustine, or ketoconazole. The men who received radium-223 had improvement in bone pain and also experienced an increased survival.